Free Trial

Establishment Labs (ESTA) FDA Approvals

Establishment Labs logo
$64.22 +0.16 (+0.25%)
As of 10:40 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Establishment Labs' Drug in the FDA Approval Process

This section highlights FDA-related milestones and regulatory updates for drugs developed by Establishment Labs (ESTA). Over the past two years, Establishment Labs has reported clinical trial outcomes, regulatory submissions, approvals, and other FDA events for drugs and therapies such as Motiva. For definitions of regulatory abbreviations such as NDA, BLA, or PDUFA, see the event status legend.

Motiva Flora® SmoothSilk® FDA Regulatory Events

Motiva Flora® SmoothSilk® is a drug developed by Establishment Labs for the following indication: Tissue Expander. This drug is under review by the U.S. Food and Drug Administration (FDA). Below is a timeline of key regulatory milestones for this therapy.

Establishment Labs FDA Events - Frequently Asked Questions

As of now, Establishment Labs (ESTA) has not received any FDA approvals for its therapy in the last two years.

In the past two years, Establishment Labs (ESTA) has reported FDA regulatory activity for Motiva Flora® SmoothSilk®.

The most recent FDA-related event for Establishment Labs occurred on October 5, 2026, involving Motiva Flora® SmoothSilk®. The update was categorized as "Approved," with the company reporting: "Establishment Labs Holdings Inc announced that the U.S. Food and Drug Administration (FDA) has approved an expanded range of Motiva SmoothSilk® Round and Motiva SmoothSilk Ergonomix® breast implants for use in the United States."

Currently, Establishment Labs has one therapy (Motiva Flora® SmoothSilk®) targeting the following condition: Tissue Expander..

  • NDA: New Drug Application
  • ANDA: Abbreviated New Drug Application
  • sNDA: Supplemental New Drug Application
  • BLA: Biologics License Application
  • sBLA: Supplemental Biologics License Application
  • FDA Approved: Approved by the FDA
  • EMA: European Medicines Agency
  • CE Mark: European Union Certification
  • NMPA: China National Medical Products Administration
  • MHLW: Japanese Ministry of Health
  • FDA Meeting: Consultation with FDA
  • Pre-IND: Pre-Investigational New Drug Meeting
  • Breakthrough Therapy: Special FDA designation for promising therapies
  • Fast Track: Accelerated FDA approval pathway
  • Orphan Drug: Designation for rare disease treatments
  • RPD: Rare Pediatric Disease Designation
  • RMAT: Regenerative Medicine Advanced Therapy
  • DSMB Review: Data Safety Monitoring Board Review
  • IDMC Review: Independent Data Monitoring Committee
  • MAA: MHRA Marketing Authorization Application
  • RTF: Refusal to File (Rejected Application)
  • 510(k): FDA Clearance for Medical Devices
  • Rolling Submission: Staggered regulatory review process

FDA progress for NASDAQ:ESTA last updated on 10/5/2026 by MarketBeat.com Staff. We continuously monitor for new FDA events and market data.
From Our Partners